Inmagene Biopharmaceuticals, a China-based global clinical-stage biotechnology company, announced on Sunday that it has received approval from the United States Food and Drug Administration (FDA) for its investigational new drug (IND) application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (BTK) inhibitor, to proceed to a Phase one clinical trial.
The company is producing the drug candidate to potentially treat immunological diseases.
The proposed Phase one study, a double-blind, randomised, placebo-controlled, single and multiple dose escalation study in healthy subjects, intends to explore the product's safety, tolerability, pharmacokinetics, and pharmacodynamics.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress